Skip to content

Lung adenocarcinoma — ALK, ROS1, RET, and NTRK fusion drivers

TL;DR — ALK, ROS1, RET, and NTRK fusions define uncommon but treatment-critical adenocarcinoma subsets enriched in never-smokers and younger patients. Modern inhibitors produce response rates and intracranial control that make fusion detection before first-line therapy essential: alectinib and lorlatinib displaced crizotinib in ALK disease, repotrectinib expands ROS1 options, and selpercatinib beat platinum-pemetrexed with pembrolizumab in untreated RET-fusion disease (Peters 2017, PMID 28586279; Shaw 2020, PMID 33207094; Drilon 2024, PMID 38197815; Zhou 2023, PMID 37870973). The recurring failure mode is the central nervous system, where drug penetration and solvent-front resistance matter as much as extracranial response. RNA-capable testing is important because DNA panels can miss or fail to resolve fusions, particularly those involving large introns or novel partners (Lindeman 2018, PMID 29398453). These are chronic evolutionary diseases: sequential therapy selects kinase-domain mutations, bypass signaling, and lineage change rather than producing a single universal resistance mechanism.

One histology, four fusion families

Driver Typical molecular event Approximate clinical frequency First-line evidence anchor Principal biological caveat
ALK EML4–ALK and rarer partners ~3%–7% of advanced nonsquamous NSCLC ALEX and CROWN (PMIDs: 28586279, 33207094) Fusion variant and compound resistance affect later sequencing
ROS1 CD74–ROS1 and diverse partners ~1%–2% PROFILE 1001, entrectinib, TRIDENT-1 (PMIDs: 25264305, 31838015, 38197815) CNS escape and G2032R solvent-front resistance
RET KIF5B–RET, CCDC6–RET ~1%–2% LIBRETTO-431 (PMID 37870973) Selective RET inhibition should precede empiric immunotherapy
NTRK1/2/3 Multiple tissue-agnostic fusions Usually <1% in NSCLC Larotrectinib pooled trials (PMID 29466156) True oncogenic fusions must be separated from expression or nonfunctional rearrangements

Frequency estimates vary with ancestry, smoking distribution, assay, stage, and whether the denominator is all NSCLC or adenocarcinoma. They are prevalence priors, never reasons to omit testing (TCGA 2014, PMID 25079552; Lindeman 2018, PMID 29398453).

Detection: why RNA matters

Fusions can be detected by break-apart FISH, immunohistochemistry, DNA sequencing, RNA sequencing, or combinations. IHC can screen ALK efficiently, but broad multiplex sequencing preserves tissue and detects several driver classes together (Lindeman 2018, PMID 29398453; Yu 2019, PMID 30243889).

Problem Consequence Practical response
Large or repetitive introns DNA capture may not span a breakpoint Add RNA-based fusion testing when DNA is negative or equivocal
Low tumor fraction False-negative tissue or plasma result Confirm adequacy; use complementary tissue/plasma sampling
Novel fusion partner Bioinformatic filtering may discard a real event Review read support, reading frame, kinase-domain retention, and RNA expression
Plasma negative Absence of shedding is not absence of fusion Reflex to tissue; a negative plasma test is non-exclusionary (Rolfo 2021, PMID 34246791)
Multiple apparent drivers Possible artifact, heterogeneity, or acquired bypass Molecular-tumor-board review and orthogonal confirmation

ALK-positive disease

From crizotinib to CNS-active inhibitors

ALEX randomized untreated ALK-positive advanced NSCLC to alectinib or crizotinib. Alectinib prolonged progression-free survival and markedly reduced CNS progression, establishing intracranial efficacy as a first-line criterion rather than a salvage attribute (Peters 2017, PMID 28586279; Gadgeel 2018, PMID 30215676).

CROWN randomized lorlatinib against crizotinib. Lorlatinib produced prolonged systemic and intracranial disease control, but its lipid, edema, weight, neurocognitive, and mood adverse-event profile differs from alectinib's hepatic, muscular, constipation, edema, and bradycardia profile (Shaw 2020, PMID 33207094; ALK bradycardia synthesis, PMID 34492553).

There is no mature head-to-head randomized alectinib-versus-lorlatinib trial. Cross-trial comparisons are distorted by imaging schedules, CNS eligibility, crossover, follow-up, and differing comparator performance (network meta-analysis, PMID 34139965).

Decision Evidence that favors one approach Remaining uncertainty
Maximum early CNS protection Lorlatinib's potent intracranial activity in CROWN (PMID 33207094) Long-term neurocognitive burden and sequencing cost
Familiar chronic tolerability Alectinib experience and ALEX CNS benefit (PMIDs: 28586279, 30215676) Whether reserving lorlatinib sacrifices preventable CNS control
Baseline brain metastases Both agents are CNS active Lesion size, symptoms, local-therapy timing, and adherence alter the choice
Frailty or polypharmacy Toxicity profile and interactions dominate Trial populations underrepresent complex multimorbidity

ALK resistance

On-target ALK mutations, amplification, bypass signaling, and histologic transformation can coexist. Successive inhibitors can select compound ALK mutations that are not predicted by a simple “next generation” hierarchy. Re-biopsy or plasma genotyping is most useful when its result could alter the next drug, local-treatment plan, or trial eligibility.

Oligoprogression can reflect spatially limited resistant clones while the remaining disease remains ALK-dependent. Local ablation with continuation of a suppressive TKI is biologically coherent but supported mainly by nonrandomized and mixed-driver data; widespread progression should prompt a new systemic strategy.

Resected ALK-positive disease

ALINA compared two years of adjuvant alectinib with platinum chemotherapy after complete resection of stage IB–IIIA ALK-positive NSCLC and demonstrated a large disease-free-survival benefit, including CNS control (Wu 2024, PMID 38598794). The trial changes the postoperative pathway but leaves duration, mature overall survival, and treatment at relapse unresolved.

ROS1-positive disease

Crizotinib produced durable responses in ROS1-rearranged NSCLC and established ROS1 as a therapeutic target (Shaw 2014, PMID 25264305). Entrectinib added meaningful intracranial activity in pooled phase 1–2 data (Drilon 2020, PMID 31838015; updated analysis, PMID 33646820).

TRIDENT-1 evaluated repotrectinib in ROS1 fusion-positive disease, including TKI-naive and previously treated cohorts. Its compact macrocyclic design was developed to retain activity against solvent-front mutations and penetrate the CNS (Drilon 2024, PMID 38197815; FDA summary, PMID 38875108).

ROS1 state Key question Evidence boundary
TKI-naive, no CNS disease Which drug maximizes durable control with acceptable toxicity? No randomized repotrectinib-versus-entrectinib comparison
Baseline brain metastases Is intracranial response sufficient to defer radiation? Symptoms, lesion size, edema, and follow-up reliability remain decisive
G2032R after crizotinib Can a solvent-front-active inhibitor restore control? Repotrectinib cohort evidence; resistance remains heterogeneous
Progression after newer ROS1 TKI On-target versus bypass resistance Requires contemporary molecular sampling and trial access

RET fusion-positive disease

Selpercatinib produced high response rates in previously treated and untreated RET-fusion NSCLC in LIBRETTO-001 (Drilon 2020, PMID 32846060). Pralsetinib also showed activity in ARROW (Gainor 2021, PMID 34118197).

LIBRETTO-431 directly randomized first-line selpercatinib against platinum-pemetrexed with or without pembrolizumab. Median progression-free survival was 24.8 versus 11.2 months in the interim efficacy population, supporting selective RET inhibition before nonspecific chemo-immunotherapy (Zhou 2023, PMID 37870973).

RET solvent-front and gate-region mutations, MET amplification, and other bypass events can cause resistance. Structural work shows why non-gatekeeper mutations can confer cross-resistance to both selpercatinib and pralsetinib (Subbiah 2021, PMID 33161056).

NTRK fusion-positive disease

NTRK fusions are rare in lung cancer but actionable across tissue types. Larotrectinib's pooled early trials demonstrated high response rates across TRK-fusion cancers, with responses independent of age and tumor type in a small heterogeneous dataset (Drilon 2018, PMID 29466156; pooled analysis, PMID 32105622).

Because the prior probability is low, assay specificity is crucial. Pan-TRK IHC is a screen, not definitive proof in lung cancer; RNA confirmation is valuable for unusual DNA rearrangements (NTRK lung-cancer review, PMID 38733648).

Acquired kinase-domain solvent-front, gatekeeper, and xDFG mutations motivated next-generation TRK inhibitors. Access is generally through tissue-agnostic labels or trials, and NSCLC-specific denominators remain small.

Brain metastases: a shared design requirement

Domain Minimum useful evidence
Baseline activity Intracranial response with measurable-lesion denominator
Prevention Time to CNS progression in patients without baseline disease
Durability Intracranial duration of response and competing extracranial progression
Safety Edema, hemorrhage, radionecrosis interactions, neurocognitive toxicity
Sequencing Outcomes after prior radiotherapy and prior CNS-active TKI

The CNS is a pharmacologic sanctuary and an independent source of morbidity. “Brain-active” should not be inferred from systemic response alone; it requires prespecified CNS assessment (ALEX CNS analysis, PMID 30215676; entrectinib analysis, PMID 31838015; TRIDENT-1, PMID 38197815).

Safety signatures

Class Characteristic risks requiring longitudinal monitoring
Alectinib Hepatic injury, creatine-kinase elevation, myalgia, constipation, edema, bradycardia
Lorlatinib Hyperlipidemia, edema, weight gain, neuropathy, cognitive/mood effects, interactions
Crizotinib Visual disturbance, edema, hepatic toxicity, bradycardia, QT prolongation
Entrectinib/repotrectinib Dizziness, dysgeusia, paresthesia, ataxia; weight and CNS effects vary
Selpercatinib/pralsetinib Hypertension, hepatic toxicity, QT effects; pneumonitis and marrow effects vary
TRK inhibitors Dizziness, neurologic symptoms, weight gain, withdrawal pain after interruption

Exact monitoring and dose-modification rules are product- and jurisdiction-specific; see red flags and safety concerns.

Open questions

  • Does first-line lorlatinib improve lifetime quality-adjusted survival versus alectinib followed by lorlatinib, rather than only first progression (PMIDs: 33207094, 28586279)?
  • Which ALK fusion variants and co-alterations should change first-line selection or surveillance (PMID 30902613)?
  • Can local therapy plus continued TKI be prospectively defined by molecularly confirmed oligoprogression?
  • Which ROS1 inhibitor sequence best suppresses G2032R and compound resistance while preserving CNS control (PMID 38197815)?
  • Can postoperative fusion-targeted therapy produce cure rather than delay, and which ctDNA state should guide duration (ALINA, PMID 38598794)?
  • How should ultra-rare NTRK-positive lung cohorts be analyzed without losing tissue-specific safety and natural-history information (PMID 32105622)?

References

  1. Peters S, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017. PMID 28586279
  2. Gadgeel S, et al. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study. Ann Oncol. 2018. PMID 30215676
  3. Shaw AT, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med. 2020. PMID 33207094
  4. Zhou C, et al. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study. Lancet Respir Med. 2019. PMID 30981696
  5. Camidge DR, et al. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. J Thorac Oncol. 2019. PMID 30902613
  6. Cirne F, et al. ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis. Lung Cancer. 2021. PMID 34492553
  7. Wang L, et al. Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor-naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis. J Chemother. 2022. PMID 34139965
  8. Wu YL, et al. Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024. PMID 38598794
  9. Shaw AT, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014. PMID 25264305
  10. Drilon A, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020. PMID 31838015
  11. Dziadziuszko R, et al. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021. PMID 33646820
  12. Drilon A, et al. Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2024. PMID 38197815
  13. Barbato MI, et al. FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer. Clin Cancer Res. 2024. PMID 38875108
  14. Yun MR, et al. Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front-Mutant ROS1-Rearranged Non-Small Cell Lung Cancer. Clin Cancer Res. 2020. PMID 32269053
  15. Drilon A, et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2020. PMID 32846060
  16. Zhou C, et al. First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC. N Engl J Med. 2023. PMID 37870973
  17. Gainor JF, et al. Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. Lancet Oncol. 2021. PMID 34118197
  18. Subbiah V, et al. Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. Ann Oncol. 2021. PMID 33161056
  19. Drilon A, et al. Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med. 2018. PMID 29466156
  20. Hong DS, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020. PMID 32105622
  21. Repetto M, et al. NTRK gene fusion testing and management in lung cancer. Cancer Treat Rev. 2024. PMID 38733648
  22. Lindeman NI, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Mol Diagn. 2018. PMID 29398453
  23. Rolfo C, et al. Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer. J Thorac Oncol. 2021. PMID 34246791
  24. Yu TM, et al. Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis. Clin Lung Cancer. 2019. PMID 30243889
  25. Cancer Genome Atlas Research Network, et al. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014. PMID 25079552